Ph 1b trial of elraglusib, retifanlimab, and mFOLFIRINOX combo as 1L therapy in advanced pancreatic adenocarcinoma initiated
“We believe the combination of elraglusib with retifanlimab and mFOLFIRINOX represents a novel and mechanistically compelling strategy to address unmet needs in advanced pancreatic adenocarcinoma,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “The collaboration with UPMC Hillman Cancer Center and Incyte enables us to explore new synergistic opportunities for patients who have not yet received systemic therapy and builds on the momentum of our ongoing clinical programs. The study further allows us to assess ways to optimize elraglusib’s potential through a complementary multi-agent approach designed to enhance both efficacy and durability of response.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo